Newly Diagnosed Standard Risk B Precursor ALL Study

Newly Diagnosed Standard Risk B Precursor ALL Study

Share this:

Treatment for Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (ALL).

PROTOCOL ID

COG # AALL0932

PROTOCOL DESCRIPTION

This study is for patients with newly diagnosed standard risk B-precursor acute lymphoblastic leukemia (ALL)

ELIGIBILITY CRITERIA

  • Patients must have newly diagnosed NCI standard risk B-precursor ALL.
  • Patients must be greater than 365 days and less than 10 years of age.
  • Patients must be enrolled on AALL08B1 prior to enrollment on AALL0932.
  • Patients must have an initial white blood count of less than 50,000.
  • Patients with Down Syndrome are eligible.

Primary Investigator(s)

Mandy Atkinson, M.D.

Contact Information

Wendy McCarty, Clinical Research Coordinator
Office: 540-981-7376
wpmccarty@carilionclinic.org